Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895640 | 0.84 | CSNK2A2 (0.56) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL3835960 | 0.80 | MAP3K8 (0.39) | CSNK2A2CSNK2BCSNK2A1KDRHSP90AB1 | |
| SCHEMBL763925 | 0.76 | TSHR (0.43) | — | |
| SCHEMBL14163467 | 0.67 | PDE4D (0.47) | CSNK2A2CSNK2BCSNK2A1KDR | |
| SCHEMBL3816187 | 0.66 | MAPK1 (0.41) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL15514276 | 0.65 | CSNK2A2 (0.58) | CSNK2A2CSNK2BCSNK2A1KDRHSP90AB1 | |
| SCHEMBL3881086 | 0.61 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL14543518 | 0.59 | ADORA2A (0.50) | KDR | |
| SCHEMBL17514108 | 0.53 | MAPK1 (0.42) | KDRILK | |
| SCHEMBL16929779 | 0.53 | JAK2 (0.58) | ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595320-B2 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CASP3 | CSNK2A2 885/4885CSNK2B 821/4885CSNK2A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.